The effect of taurine on hepatic steatosis induced by thioacetamide in Zebrafish (Danio rerio)

Digestive Diseases and Sciences

Volumn 57, Issue 3, 2012, Pages 675-682

  Hammes, Thais Ortiz ^a,b   Pedroso, Gabriela Lima ^a,b   Hartmann, Carolina Rigatti ^a   Escobar, Thayssa Dalla Costa ^a   Fracasso, Laisa Beduschi ^a   Da Rosa, Darlan Pase ^a,b   Marroni, Norma Possa ^a,b,c   Porawski, Marilene ^a   Da Silveira, Themis Reverbel ^a,b  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c UNIVERSIDADE LUTERANA DO BRASIL   (Brazil)

Author keywords

Nonalcoholic fatty liver disease; SIRT1; Taurine; Thioacetamide; Zebrafish

Indexed keywords

ADIPONECTIN RECEPTOR 2; MESSENGER RNA; SIRTUIN 1; SUPEROXIDE DISMUTASE; TAURINE; THIOACETAMIDE; TRIACYLGLYCEROL; ADIPONECTIN RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; ZEBRAFISH PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FATTY LIVER; FEMALE; HISTOPATHOLOGY; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRIACYLGLYCEROL BLOOD LEVEL; ZEBRA FISH; ANIMAL; BLOOD; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG EFFECT; GENETICS; LIPID METABOLISM; LIPID PEROXIDATION; LIVER; PATHOLOGY;

ANIMALS; DISEASE MODELS, ANIMAL; FATTY LIVER; FEMALE; LIPID METABOLISM; LIPID PEROXIDATION; LIVER; MALE; OXIDATIVE STRESS; RECEPTORS, ADIPONECTIN; SIRTUIN 1; TAURINE; THIOACETAMIDE; TRIGLYCERIDES; TUMOR NECROSIS FACTOR-ALPHA; ZEBRAFISH; ZEBRAFISH PROTEINS;

EID: 84859515960     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-011-1931-4     Document Type: Article

References (50)

1. Roberts EA. Pediatric nonalcoholic fatty liver disease (NAFLD): a "growing" problem? J Hepatol. 2007;46:1133-1142. (Pubitemid 46680362)
2. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221-1231.
3. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40:1387-1395. (Pubitemid 39657013)
4. Moretto M, Kupski C, Mottin CC, et al. Hepatic steatosis in patients undergoing bariatric surgery and its relationship to body mass index and co-morbidities. Obes Surg. 2003;13:622-624. (Pubitemid 36951745)
5. Cotrim HP, Parise ER, Oliveira CP, et al. Nonalcoholic fatty liver disease in Brazil. Clinical and histological profile. Ann Hepatol. 2011;10:33-37.
6. OH MK, Winn J, Poordad F. Review article: diagnosis and treatment of non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2008;28:503-522.
7. Huxtable RJ. Physiological actions of taurine. Physiol Rev. 1992;72:101-163.
8. Balkan J, Dogru-Abbasoglu S, Kanbagli O, et al. Taurine has a protective effect against thioacetamide-induced liver cirrhosis by decreasing oxidative stress. Hum Exp Toxicol. 2001;20:251-254.
9. Chen SW, Chen YX, Shi J, et al. The restorative effect of taurine on experimental nonalcoholic steatohepatitis. Dig Dis Sci. 2006;51:2225-2234.
10. Lam SH, Gong Z. Modeling liver cancer using zebrafish: a comparative oncogenomics approach. Cell Cycle. 2006;5: 573-577.
11. Passeri MJ, Cinaroglu A, Gao C, et al. Hepatic steatosis in response to acute alcohol exposure in zebrafish requires sterol regulatory element binding protein activation. Hepatology. 2009;49:443-452.
12. Rekha RD, Amali AA, Her GM, et al. Thioacetamide accelerates steatohepatitis, cirrhosis and HCC by expressing HCV core protein in transgenic zebrafish Danio rerio. Toxicology. 2008;243:11-22. (Pubitemid 350258587)
13. Amali AA, Rekha RD, Lin CJ, et al. Thioacetamide induced liver damage in zebrafish embryo as a disease model for steatohepatitis. J Biomed Sci. 2006;13:225-232.
14. McGrath P, Li CQ. Zebrafish: a predictive model for assessing drug-induced toxicity. Drug Discov Today. 2008;13:394-401.
15. Kinkel AD, Fernyhough ME, Helterline DL, et al. Oil red-O stains non-adipogenic cells: a precautionary note. Cytotechnology. 2004;46:49-56. (Pubitemid 40897995)
16. Jagadeeswaran P, Sheehan JP, Craig FE, et al. Identification and characterization of zebrafish thrombocytes. Br J Haematol. 1999;107:731-738. (Pubitemid 30020143)
17. Buege JA, Aust SD. Microsomal lipid peroxidation. Methods Enzymol. 1978;52:302-310.
18. Misra HP, Fridovich I. The role of superoxide anion in the autoxidation of epinephrine and a simple assay for superoxide dismutase. J Biol Chem. 1972;247:3170-3175.
19. Boveris A, Chance B. The mitochondrial generation of hydrogen peroxide. General properties and effect of hyperbaric oxygen. Biochem J. 1973;134:707-716.
20. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-254.
21. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2[-delta delta C(T)] method. Methods. 2001;25:402-408. (Pubitemid 34164012)
22. Lewis J, Mohanty S. Nonalcoholic fatty liver disease: a review and update. Dig Dis Sci. 2010;55:560-578.
23. Day CP. Pathogenesis of steatohepatitis. Best Pract Res Clin Gastroenterol. 2002;16:663-678.
24. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology. 1998;114:842-845.
25. Tiniakos DG, Vos MB, Brunt EM. Nonalcoholic fatty liver disease: pathology and pathogenesis. Annu Rev Pathol. 2010;5: 145-171.
26. Chilakapati J, Shankar K, Korrapati MC, et al. Saturation toxicokinetics of thioacetamide: role in initiation of liver injury. Drug Metab Dispos. 2005;33:1877-1885. (Pubitemid 41697274)
27. Tunez I, Munoz MC, Villavicencio MA, et al. Hepato-and neurotoxicity induced by thioacetamide: protective effects of melatonin and dimethylsulfoxide. Pharmacol Res. 2005;52: 223-228. (Pubitemid 40981922)
28. Dogru-Abbasoglu S, Kanbagli O, Balkan J, et al. The protective effect of taurine against thioacetamide hepatotoxicity of rats. Hum Exp Toxicol. 2001;20:23-27. (Pubitemid 32372413)
29. Law K, Brunt EM. Nonalcoholic fatty liver disease. Clin Liver Dis. 2010;14:591-604.
30. Yamaguchi K, Yang L, McCall S, et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology. 2007;45:1366-1374. (Pubitemid 46918320)
31. Dowman JK, Tomlinson JW, Newsome PN. Pathogenesis of nonalcoholic fatty liver disease. Qjm. 2010;103:71-83.
32. Assy N, Kaita K, Mymin D, et al. Fatty infiltration of liver in hyperlipidemic patients. Dig Dis Sci. 2000;45:1929-1934.
33. Tasci I, Mas N, Mas MR, et al. Ultrastructural changes in hepatocytes after taurine treatment in CCl4 induced liver injury. World J Gastroenterol. 2008;14:4897-4902.
34. Chen X, Sebastian BM, Tang H, et al. Taurine supplementation prevents ethanol-induced decrease in serum adiponectin and reduces hepatic steatosis in rats. Hepatology. 2009;49: 1554-1562.
35. Schaffer SW, Azuma J, Mozaffari M. Role of antioxidant activity of taurine in diabetes. Can J Physiol Pharmacol. 2009;87:91-97.
36. Lakshmi Devi S, Anuradha CV. Mitochondrial damage, cytotoxicity and apoptosis in iron-potentiated alcoholic liver fibrosis: amelioration by taurine. Amino Acids. 2010;38:869-879.
37. Rosemberg DB, da Rocha RF, Rico EP, et al. Taurine prevents enhancement of acetylcholinesterase activity induced by acute ethanol exposure and decreases the level of markers of oxidative stress in zebrafish brain. Neuroscience. 2010;171:683-692.
38. Oliveira MW, Minotto JB, de Oliveira MR, et al. Scavenging and antioxidant potential of physiological taurine concentrations against different reactive oxygen/nitrogen species. Pharmacol Rep. 2010;62:185-193.
39. Oliveira CP, Coelho AM, Barbeiro HV, et al. Liver mitochondrial dysfunction and oxidative stress in the pathogenesis of experimental nonalcoholic fatty liver disease. Braz J Med Biol Res. 2006;39:189-194.
40. Videla LA, Rodrigo R, Orellana M, et al. Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patients. Clin Sci (Lond). 2004;106:261-268. (Pubitemid 38365832)
41. Yesilova Z, Yaman H, Oktenli C, et al. Systemic markers of lipid peroxidation and antioxidants in patients with nonalcoholic fatty liver disease. Am J Gastroenterol. 2005;100:850-855. (Pubitemid 40592378)
42. Chang YY, Chou CH, Chiu CH, et al. Preventive effects of taurine on development of hepatic steatosis induced by a high-fat/ cholesterol dietary habit. J Agric Food Chem. 2011;59:450-457.
43. Malaguarnera M, Di Rosa M, Nicoletti F, et al. Molecular mechanisms involved in NAFLD progression. J Mol Med. 2009;87:679-695.
44. Jou J, Choi SS, Diehl AM. Mechanisms of disease progression in nonalcoholic fatty liver disease. Semin Liver Dis. 2008;28: 370-379.
45. Kaser S, Moschen A, Cayon A, et al. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut. 2005;54:117-121. (Pubitemid 40007229)
46. Banks AS, Kon N, Knight C, et al. SirT1 gain of function increases energy efficiency and prevents diabetes in mice. Cell Metab. 2008;8:333-341.
47. Colak Y, Ozturk O, Senates E, et al. SIRT1 as a potential therapeutic target for treatment of nonalcoholic fatty liver disease. Med Sci Monit. 2011;17:HY5-HY9.
48. Pereira TCB, Rico EP, Rosemberg DB, et al. Zebrafish as a model organism to evaluate drugs potentially able to modulate sirtuin expression. Zebrafish. 2011;8:9-16.
49. Deng XQ, Chen LL, Li NX. The expression of SIRT1 in nonalcoholic fatty liver disease induced by high-fat diet in rats. Liver Int. 2007;27:708-715.
50. dos Costa CS, Hammes TO, Rohden F, et al. SIRT1 transcription is decreased in visceral adipose tissue of morbidly obese patients with severe hepatic steatosis. Obes Surg. 2010;20:633-639.